, Tracking Stock Market Picks
Enter Symbol:
Aeterna Zentaris, Inc. (AEZS) [hlAlert]

Speculative Buy
down 99.36 %

Aeterna Zentaris, Inc. (AEZS) rated Speculative Buy with price target $4 by Canaccord Genuity

Posted on: Wednesday,  Apr 27, 2011  11:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Speculative Buy Aeterna Zentaris, Inc. (NASDAQ: AEZS) on 04/27/2011, when the stock price was $14.22.
Since then, Aeterna Zentaris, Inc. has lost 99.37% as of 12/02/2015's recent price of $0.09.
If you would have followed this Canaccord Genuity's recommendation on AEZS, you would have lost 99.36% of your investment in 1680 days.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology. The product pipeline of the Company encompasses compounds at all stages of development, from drug discovery through marketed products. The Company’s principal product candidates include cetrorelix for benign prostatic hyperplasia (BPH) and AEZS-108 for endometrial and ovarian cancers. In January 2007, the Company completed the spin-off of Atrium Biotechnologies Inc., known as Atrium Innovations (Atrium). On November 30, 2007, the Company completed the sale of its Utah-based subsidiary, Echelon Biosciences Inc. (Echelon), to Frontier Scientific Inc.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/27/2011 11:25 AM Buy
14.22 24.00
as of 12/30/2011
1 Week down  -2.53 %
1 Month down  -3.75 %
3 Months up  1.31 %
1 YTD down  -35.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy